Histopathological analysis of retinopathy of prematurity after intravitreal bevacizumab

Carson R Bee; Christopher K H Burris; Heather A D Potter; Devasis Reddy; Kenneth B Simons; Deborah M Costakos

doi:10.1016/j.jaapos.2016.11.025

Histopathological analysis of retinopathy of prematurity after intravitreal bevacizumab

J AAPOS. 2017 Apr;21(2):159-160. doi: 10.1016/j.jaapos.2016.11.025. Epub 2017 Feb 17.

Authors

Carson R Bee¹, Christopher K H Burris², Heather A D Potter², Devasis Reddy², Kenneth B Simons¹, Deborah M Costakos³

Affiliations

¹ Medical College of Wisconsin, The Eye Institute, Milwaukee, Wisconsin.
² University of Wisconsin, Madison, Wisconsin.
³ Medical College of Wisconsin, The Eye Institute, Milwaukee, Wisconsin. Electronic address: dcostakos@mcw.edu.

PMID: 28219740
DOI: 10.1016/j.jaapos.2016.11.025

Abstract

We report the case of a premature infant with end-organ failure who developed high-risk retinopathy of prematurity (ROP) bilaterally and was treated with intravitreal bevacizumab (IVB) injection therapy with regression noted on follow-up clinical examination. The infant died 3 weeks after IVB injection therapy. Histopathological analysis was conducted on bilateral globes and revealed persistent preretinal vessels.

Publication types

Case Reports

MeSH terms

Angiogenesis Inhibitors / administration & dosage
Bevacizumab / administration & dosage*
Cell Proliferation
Endothelium, Vascular / pathology
Fatal Outcome
Humans
Infant
Infant, Premature*
Intravitreal Injections
Laser Coagulation
Male
Multiple Organ Failure / complications
Retina / pathology*
Retinopathy of Prematurity / complications
Retinopathy of Prematurity / pathology*
Retinopathy of Prematurity / therapy
Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

Angiogenesis Inhibitors
Vascular Endothelial Growth Factor A
Bevacizumab